Pat Metharom's Bibliography

1 Herrmann, F. Clinical application of gene transfer. J. Mol. Med. 1996. 74: 213-221.

2 Kefford, R. Regulatory issues in gene therapy in Australia and the NHMRC GTC. "The Boden Conference on Gene Therapy" publication. 1996.

3 Somatic gene therapy (supplementary note 7). NHMRC statement on Human Experimentation. 1992. http://www.law.newcastle.edu.au./centre/nhmrc/statem.htm

4 Como, N.D., ed. Mosby's Dictionary: Medical, Nursing, & Allied Health, 3rd ed. The C.V. Mosby Company. 1990. p332

5 Gregory, R. J., et al. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature. 1990. 347: 382-386.

6 Welsh, M. J., et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993. 73: 1251-1254.

7 Zielenski, J., et al. Cystic Fibrosis: Genotypic and phenotypic variations. Annu. Rev. Genetics. 1995. 29: 777-807.

8 Williams, J., ed. Cystic fibrosis information manual. The Cystic Fibrosis Association of Queensland Ltd. 1994.

9 Collins, F. S. Cystic fibrosis: Molecular biology and therapeutic implications. Science. 1992. 256: 774-777.

10 Shale, D. Management in adults. Shale, D. J., ed. Cystic Fibrosis. BMJ Publishing Group. 1996. pp14-31.

11 Dark, J., et al. Transplantation. Shale, D. J., ed. Cystic Fibrosis. BMJ Publishing Group. 1996. pp120-133.

12 Howard, M., et al. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutation. Nature Med. 1996. 2:467-469.

13 Lewin, B. Gene V. Oxford University Press. 1994. pp192, 219

14 Haws, C. M., et al. D F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 1996. 270: C1544-C1555.

15 Delaney, S. J., et al. New pharmaceutical approaches to the treatment of cystic fibrosis. Nature Medicine. 1996. 2(4): 392-393.

16 Chang, S. H., et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990. 63: 827-834.

17 Kartner, N., et al. Mislocalization of D F508 CFTR in cystic fibrosis sweat gland. Nature Getnetics. 1992. 1: 321-327.

18 Madden, B. P. Lung transplantation. Hodson, M. E., et al, ed. Cystic Fibrosis, 2nd ed. Chapman & Hall. 1995. pp329-346.

19 Stutts, M. J., et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995. 269: 847-850.

20 Curiel, D. T., et al. Gene therapy approaches for inherited and acquired lung diseases. Am. J. Respir. Cell Mol. Bio. 1996. 14: 1-18.

21 Coutelle, C., et al. Towards gene therapy for cystic fibrosis. Dodge, J. A., et al., ed. Cystic Fibrosis-Current Topics, vol. 2. John Wiley & Sons Ltd. 1994. pp33-54.

22 Coutelle, C. Gene therapy approaches for cystic fibrosis. Biologicals. 1995. 23: 21-25.

23 Tyler, K. L., et al. Pathogenesis of viral infection. Fields, B. N., et al., ed. Virology, vol. 2, 2nd ed. Raven Press, Ltd. 1991. pp191-239.

24 Yang, Y., et al. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. Journal of Virology. 1996. 70: 7209-7212.

25 Miller, A. D. Human gene therapy comes of age. Nature. 1992. 357: 455-460.

26 Strauss, M. Gene transfer on its long path to therapeutic application. J. Mol. Med. 1996. 74: 167-169.

27 Crystal, R. G. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genetics. 1994. 8: 42-51.

28 Fisher, K. J., et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996. 217: 11-22.

29 Zabner, J. Repeat Administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 1996. 97(6): 1504-1511.

30 Chroboczek, J. Adenovirus dodecahedron, a new vector for human gene transfer. Nature Biotechnology. 1997. 15: 52-56.

31 Berns, K. I. Parvoviridae and their replication. Fields, B. N., et al, ed. Virology, vol. 2, 2nd ed. Raven Press, Ltd. 1991. pp1743-1763.

32 Samulski, R. J. Adeno-associated viral vectors. Vos, J. H., ed. Viruses in Human Gene Therapy. 1995. pp53-76.

33 Flotte, T. R. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA. 1993. 90: 10613-10617.

34 Russell, D. W., et al. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA. 1994. 91: 8915-8919.

35 Alberts, B., et al, ed. Molecular Biology of The Cell, 3rd ed. Garland Publishing, Inc. 1994. p479.

36 Gao, X., et al. Cationic liposome-mediated gene transfer. Gene Therapy. 1995. 2: 710-722.

37 Felgner, Pl L., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 1987. 84: 7413-7417.

38 Morgan, R. Retroviral vectors in human gene therapy. Vos, J. H., ed. Viruses in Human Gene Therapy. 1995. pp77-107.

39 Pavirani, A. Development aspects of gene therapy. Biologicals. 1995. 23: 3.

40 Tait, D. L., et al. Stability and toxicity of intraperitoneal LXSN-BRCA1 retroviral vector following repeat administration. "The Boden Conference on Gene Therapy" publication. 1996.

41 Anderson, W. F. Was it just stupid or are we poor educator (editorial). Human Gene Therapy. 1994. 5: 791-792.

42 Miller, D. G., et al. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 1990. 10: 4239-4242.

43 Lewis, P. F., et al. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 1994. 68: 510-516.

44 Bukrinsky, M. I., et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA. 1992. 89: 6580-6889.

45 Lewis, P., et al. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992. 11: 3053-3058.

46 Naldini, L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996. 272: 263-267.

47 Buchschacher Jr., G. L., et al. Human immunodeficiency virus vectors for inducible expression of foreign genes. Journal of Virology. 1992. 66: 2731-2739.

48 Carroll, R., et al. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. Journal of Virology. 1994. 68: 6047-6051.

49 Rolls, M. M., et al. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self replication RNA. Cell. 1994. 79: 497-506.

50 Wei, M. Personal communications. Head of Gene Therapy Unit, SASVRC, Royal Children's Hospital, Brisbane, Qld. 1997.

51 Yu, H., et al. Inducible human immunodeficiency virus type 1 packaging cell line. Journal of Virology. 1996. 70: 4530-4537.

52 Miller, A. D. Retroviral vector. Current Topics in Microbiology and Immunology. 1992. 158: 1-24.

53 Morgan, R. A., et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Research. 1992. 20: 1293-1299.

54 Buchschacher, G. L., et al. Human immunodeficiency virus vectors for inducible expression of foreign genes. Journal of Virology. 1992. 66: 2731-2739.

55 Hayashi, T., et al. RNA packaging signal of human immunodeficiency virus type 1. Virology. 1992. 188: 590-599.

56 Richardson, J. H., et al. Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5' leader region. Journal of Virology. 1993. 67: 3997-4005.

57 Kaye, J. F., et al. Cis-Acting sequences involved in human immunodeficiency virus type 1 RNA packaging. Journal of Virology. 1995. 69: 6588-6592.

New look for June 2003